+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Electrospun Transdermal Patch for Contraceptive Hormone Delivery



Electrospun Transdermal Patch for Contraceptive Hormone Delivery



Current Drug Delivery 2019



A transdermal patch for delivery of levonorgestrel (LNG) can be used for long-acting contraception. In this study, we designed and characterized a patch made of nonwoven electrospun microfibers comprised of polycaprolactone (PCL) encapsulating LNG for slow release in a mineral oil matrix. Scanning electron microscopy showed uniform, randomly oriented PCL fibers with large interconnected voids filled with mineral oil. Thermogravimetric analysis indicated that LNG loaded into PCL fibers had thermal stability up to ~200°C. Differential scanning calorimetry suggested that LNG was dispersed in the electrospun fibers without interaction between the LNG and PCL, and without formation of drug crystals. Fourier transform infrared spectrometry and X-ray diffraction results further supported the conclusion that there was no chemical drug-polymer interaction in LNG-loaded fibers. Effective in vitro flux (i) from patches into mineral oil was 1.9 µgcm-2h-1, (ii) from mineral oil across porcine skin was 4.6 µg cm-2 h-1 and (iii) from patches across porcine skin was 1.7 µgcm-2h-1, indicating that transdermal delivery rate was controlled by a combination of the patch and the skin. The LNG-loaded patches demonstrated steady delivery of LNG across skin for up to 5 days in vitro. With additional development, LNG-loaded electrospun PCL patches could be used for long-acting contraception.

(PDF emailed within 1 workday: $29.90)

Accession: 066569255

Download citation: RISBibTeXText

PMID: 30848203


Related references

Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 285(18): 2347-2354, 2001

Dissolving microneedle patch for transdermal delivery of human growth hormone. Small 7(4): 531-539, 2011

Same-day initiation of the transdermal hormonal delivery system (contraceptive patch) versus traditional initiation methods. Contraception 72(5): 333-336, 2005

Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. Journal of Clinical Pharmacology 47(4): 497-509, 2007

Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Yearbook of Obstetrics Gynecology and Women's Health 2007: 213-214, 2007

Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 72(3): 168-174, 2005

Effects of the contraceptive vaginal ring, the contraceptive transdermal patch and combined oral contraceptives on markers of hemostasis. Contraception 81(1): 88-9; Author Reply 89-90, 2010

Comparison of cycle control and side effects between transdermal contraceptive patch and an oral contraceptive in women older than 35 years. Journal of the Medical Association of Thailand 90(9): 1715-1719, 2007

Bleeding pattern and cycle control of a low-dose transdermal contraceptive patch compared with a combined oral contraceptive: a randomized study. Contraception 91(2): 113-120, 2016

Evaluation of the contraceptive efficacy, compliance, and satisfaction with the transdermal contraceptive patch system Evra: a comparison between adolescent and adult users. Archives of Gynecology and Obstetrics 283(3): 525-530, 2011

Preference for and satisfaction of Canadian women with the transdermal contraceptive patch versus previous contraceptive method: an open-label, multicentre study. Journal of Obstetrics and Gynaecology Canada 27(4): 350-359, 2005

An evaluation of the use of the transdermal contraceptive patch in adolescents. Journal of Adolescent Health 34(5): 395-401, 2004

In vivo wound healing performance of drug loaded electrospun composite nanofibers transdermal patch. International Journal of Pharmaceutics 469(1): 102-110, 2015

Transdermal contraceptive patch: Safe or risky treatment?. Paediatrics & Child Health 12(6): 505-505, 2008

Medication of the month. Evra: first contraceptive transdermal patch. Revue Medicale de Liege 58(11): 709-712, 2004